Original price was: $199.99.$169.99Current price is: $169.99.
This item has been third-party tested by accredited U.S. laboratories and confirmed to meet a minimum purity of 98% through rigorous verification standards.
Updated COA's
Secure Shipping Guaranteed
Verified for Purity
Original price was: $199.99.$169.99Current price is: $169.99.
Research Chemical products are third-party tested by MZ Biolabs, an independent laboratory based in Arizona. Each batch is analyzed to ensure accuracy, purity, and that all specifications are met.
GLP-3 Reta is an investigational peptide currently being studied in biomedical and pharmaceutical research. It belongs to a class of novel compounds designed for multi-pathway receptor targeting. While it has drawn interest in scientific studies for its potential roles in metabolic regulation and related research areas, Retatrutide remains in the experimental phase and is not approved for clinical use.
At Research Chemical, we supply GLP-3 Reta in 5mg vials with a verified purity level of ≥99%. Each batch is manufactured and bottled in the United States, with quality controlled through third-party laboratory testing.
GLP-3 Reta is being explored for its unique activity on multiple peptide receptors. Early research suggests it acts as a receptor agonist with the potential to influence pathways involved in energy regulation and metabolic function.
This multi-receptor profile makes GLP-3 Reta a compound of interest to researchers studying peptide-based therapeutics, metabolic disorders, and receptor biology. While preclinical and early studies are ongoing, its long-term applications remain under investigation.
Because GLP-3 Reta is an investigational compound, no definitive conclusions can be drawn about its clinical effects. All current interest is limited to laboratory research and mechanistic studies.
All Research Chemical peptides are bottled in the USA under strict manufacturing standards and sealed with tamper-proof caps to ensure product integrity.
GLP-3 Reta is not intended for human use under any circumstances. It is neither a drug, food, nor supplement, and has not been evaluated or approved by the FDA for medical use.
Misuse of research chemicals poses significant risks. This compound is sold strictly for laboratory research purposes, such as in vitro or animal studies conducted under appropriate institutional controls. By purchasing this product, the buyer acknowledges full responsibility for handling it in compliance with all local regulations.
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., … & Hartman, M. L. (2023). Triple–hormone-receptor agonist GLP-3 Reta for obesity—a phase 2 trial. New England Journal of Medicine, 389(6), 514-526.
Rosenstock, J., Kanapka, L. G., Morrow, L., et al. (2023). GLP-3 Reta, a novel triple agonist, for obesity: results of a randomized, double-blind, placebo-controlled, phase 2 trial. New England Journal of Medicine, 389(1), 11–24. https://doi.org/10.1056/NEJMoa2301954
Doggrell, S. A. (2023). GLP-3 Reta showing promise in obesity (and type 2 diabetes). Expert Opinion on Investigational Drugs, 32(11), 997-1001.
Ray, A. (2023). GLP-3 Reta: a triple incretin receptor agonist for obesity management. Expert Opinion on Investigational Drugs, 32(11), 1003-1008.
Research Chemical products are manufactured and bottled in the USA, tested for ≥99% purity, and securely packaged. We are committed to providing researchers with consistent, high-quality materials.
No. GLP-3 Reta is for laboratory research use only. It is not a drug, food, or dietary supplement and is not intended for human consumption.
Lyophilized GLP-3 Reta is stable at room temperature for short-term handling. For long-term storage, we recommend keeping it in a cool, dry place, with refrigeration preferred to maintain stability.
GLP-3 Reta is supplied as a lyophilized powder in 5mg vials, sealed with tamper-proof packaging to ensure product integrity.
All batches of GLP-3 Reta offered by Research Chemical are verified to be ≥99% pure, confirmed through third-party testing methods.
GLP-3 Reta is an investigational research peptide currently being studied in biomedical research. It is not approved for medical use and is supplied strictly for laboratory research purposes.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
GLP-3 Reta is being explored for its unique activity on multiple peptide receptors. Early research suggests it acts as a receptor agonist with the potential to influence pathways involved in energy regulation and metabolic function.
This multi-receptor profile makes GLP-3 Reta a compound of interest to researchers studying peptide-based therapeutics, metabolic disorders, and receptor biology. While preclinical and early studies are ongoing, its long-term applications remain under investigation.
Because GLP-3 Reta is an investigational compound, no definitive conclusions can be drawn about its clinical effects. All current interest is limited to laboratory research and mechanistic studies.
All Research Chemical peptides are bottled in the USA under strict manufacturing standards and sealed with tamper-proof caps to ensure product integrity.
GLP-3 Reta is not intended for human use under any circumstances. It is neither a drug, food, nor supplement, and has not been evaluated or approved by the FDA for medical use.
Misuse of research chemicals poses significant risks. This compound is sold strictly for laboratory research purposes, such as in vitro or animal studies conducted under appropriate institutional controls. By purchasing this product, the buyer acknowledges full responsibility for handling it in compliance with all local regulations.
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., … & Hartman, M. L. (2023). Triple–hormone-receptor agonist GLP-3 Reta for obesity—a phase 2 trial. New England Journal of Medicine, 389(6), 514-526.
Rosenstock, J., Kanapka, L. G., Morrow, L., et al. (2023). GLP-3 Reta, a novel triple agonist, for obesity: results of a randomized, double-blind, placebo-controlled, phase 2 trial. New England Journal of Medicine, 389(1), 11–24. https://doi.org/10.1056/NEJMoa2301954
Doggrell, S. A. (2023). GLP-3 Reta showing promise in obesity (and type 2 diabetes). Expert Opinion on Investigational Drugs, 32(11), 997-1001.
Ray, A. (2023). GLP-3 Reta: a triple incretin receptor agonist for obesity management. Expert Opinion on Investigational Drugs, 32(11), 1003-1008.
Join our insider list for the latest research insights, product releases, and special offers—delivered straight to your inbox.
